Synopses & Reviews
Progenitor and stem cells found in all multi-cellular organisms have the ability to renew themselves and change into a variety of diverse specialized cell types. They can now be grown and transformed into specialized cells with characteristics similar to various human tissues. Dr. Anthony Atala, the first person to construct a working human organ and who discovered the value of amniotic stem cells, has personally selected these essays by scientists who are at the forefront of progenitor and stem cell research. Part one provides an introduction to this important field while part two discusses basic principles of stem cells. Part three reviews methods for enabling stem cell therapies and the final part of the book reviews tissue specific progenitor and stem cells.
Review
"I would recommend this book to anyone looking at translational work with cell-based therapy. In a few succinct chapters the reader will understand who works in the field, what the issues with starting the cell culture process are, what alternative cell types exist and how to navigate the complex terrain of regulatory and licensing requirements."
-Mahendra Rao, Stem Cell Reviews and Reports
Synopsis
Progenitor and stem cells have the ability to renew themselves and change into a variety of specialised types, making them ideal materials for therapy and regenerative medicine. Progenitor and stem cell technologies and therapies reviews the range of progenitor and stem cells available and their therapeutic application.
Part one reviews basic principles for the culture of stem cells before discussing technologies for particular cell types. These include human embryonic, induced pluripotent, amniotic and placental, cord and multipotent stem cells. Part two discusses wider issues such as intellectual property, regulation and commercialisation of stem cell technologies and therapies. The final part of the book considers the therapeutic use of stem and progenitor cells. Chapters review the use of adipose tissue-derived stem cells, umbilical cord blood (UCB) stem cells, bone marrow, auditory and oral cavity stem cells. Other chapters cover the use of stem cells in therapies in various clinical areas, including lung, cartilage, urologic, nerve and cardiac repair.
With its distinguished editor and international team of contributors, Progenitor and stem cell technologies and therapies is a standard reference for both those researching in cell and tissue biology and engineering as well as medical practitioners investigating the therapeutic use of this important technology.
- Reviews the range of progenitor and stem cells available and outlines their therapeutic application
- Examines the basic principles for the culture of stem cells before discussing technologies for particular cell types, including human embryonic, induced pluripotent, amniotic and placental, cord and multipotent stem cells
- Includes a discussion of wider issues such as intellectual property, regulation and commercialisation of stem cell technologies and therapies
About the Author
Anthony Atala is Director of the Wake Forest Institute for Regenerative Medicine and Chair of the Department of Urology at Wake Forest University School of Medicine in North Carolina. Dr. Atala has participated in the 2011 TED Conference and his work was covered by the New York Times and the New Yorker. He has also been featured in Esquire, U.S. News and World Report and Time magazine. He has appeared on Charlie Rose, 60 Minutes and other TV programs.
Table of Contents
Part 1 Basic principles of stem cells: Basic principles for stem cell culture; Basic principles of human embryonic stem cells; Basic principles in generating induced pluirpotent stem cells; Basic principles of amniotic and placental stem cells; Basic principles of cord blood stem cells; Basic principles of multipotent stem cells|
Part 2 Enabling cell therapy: Intellectual property claims to stem cell technologies: research, clinical testing and product sales; Regulatory considerations of stem and progenitor cell-based products: US Food and Drug Administration; Cell therapy commercialisation; Stem cell tourism
Part 3 Tissue specific progenitor cells: Adipose tissue-derived stem cell biology and therapy; Umbilical cord blood (UCB) progenitor stem cell biology and therapy; Auditory progenitor stem cell biology and therapy; Olfactory mucosa: neural stem and progenitor cells for nervous system repair and cell models of brain disease; Oral cavity progenitor and stem cell biology and therapy; Bone marrow mesenchymal progenitor and stem cell biology and therapy; Progenitor and stem cell therapies for cartilage repair; Cardiac stem and progenitor cell biology and therapy; Renal progenitor and stem cell biology and therapy; Lung progenitor and stem cell biology and therapy; Genitourinary progenitor and stem cell biology and therapy